Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine

被引:25
作者
Tissot, Noemie [1 ]
Brunel, Anne-Sophie [1 ]
Bozon, Fabienne [1 ]
Rosolen, Beatrice [1 ]
Chirouze, Catherine [1 ,2 ]
Bouiller, Kevin [1 ,2 ]
机构
[1] Ctr Hosp Reg Univ, Malad Infect & Trop, F-25030 Besancon, France
[2] Univ Bourgogne Franche Comte, UMR CNRS Chronoenvironm 6249, F-25000 Besancon, France
关键词
COVID-2019; Pfizer-BioNTech COVID-19 vaccine; COVID-19; vaccine; Vaccine reactogenicity; SARS-CoV; 2; Side effects;
D O I
10.1016/j.vaccine.2021.07.047
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: COVID-19 vaccination seems to be the most pertinent pharmacologic public health measure to control the pandemic. Reactogenicity symptoms were frequent in vaccine recipients mostly mild to moderate and commonly reported after the second dose. However, there is a lack of data in patients with a previous diagnosis of Covid-19. Methods: We analysed side effects of 311 patients after the first dose of Pfizer-BioNTech COVID-19 vac-cine, in a french university hospital. We compared patients with COVID-19 history to naive individuals. All the data collected are based on self-reported, including COVID-19 exposure status. Results: Overall, 229 (74%) patients reported at least one side effect. Among participants with history of Covid-19, 95% reported at least one adverse event versus 70% in naive patients (p < 0.01). However, symp-tom intensity was not different between the 2 groups. Conclusion: Vaccine recipients with prior COVID-19 reported more, but no more serious, side effects than naive participants. (c) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5087 / 5090
页数:4
相关论文
共 7 条
[1]  
[Anonymous], 2021, REACT ADV EV PFIZ BI REACT ADV EV PFIZ BI
[2]  
[Anonymous], Strategie de vaccination contre le SARS-CoV-2-Place du vaccin a ARNm COMIRNATY ~ (BNT162b2)
[3]  
[Anonymous], 2021, BIONTECH SE PHAS 1 BIONTECH SE PHAS 1
[4]  
Commissioner O of the, 2021, PFIZ BIONTECH COVID
[5]   Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine [J].
Krammer, Florian ;
Srivastava, Komal ;
Simon, Viviana .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14) :1372-1374
[6]   Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J].
Polack, Fernando P. ;
Thomas, Stephen J. ;
Kitchin, Nicholas ;
Absalon, Judith ;
Gurtman, Alejandra ;
Lockhart, Stephen ;
Perez, John L. ;
Perez Marc, Gonzalo ;
Moreira, Edson D. ;
Zerbini, Cristiano ;
Bailey, Ruth ;
Swanson, Kena A. ;
Roychoudhury, Satrajit ;
Koury, Kenneth ;
Li, Ping ;
Kalina, Warren V. ;
Cooper, David ;
Frenck, Robert W., Jr. ;
Hammitt, Laura L. ;
Tureci, Ozlem ;
Nell, Haylene ;
Schaefer, Axel ;
Unal, Serhat ;
Tresnan, Dina B. ;
Mather, Susan ;
Dormitzer, Philip R. ;
Sahin, Ugur ;
Jansen, Kathrin U. ;
Gruber, William C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) :2603-2615
[7]   Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates [J].
Walsh, Edward E. ;
Frenck, Robert W., Jr. ;
Falsey, Ann R. ;
Kitchin, Nicholas ;
Absalon, Judith ;
Gurtman, Alejandra ;
Lockhart, Stephen ;
Neuzil, Kathleen ;
Mulligan, Mark J. ;
Bailey, Ruth ;
Swanson, Kena A. ;
Li, Ping ;
Koury, Kenneth ;
Kalina, Warren ;
Cooper, David ;
Fontes-Garfias, Camila ;
Shi, Pei-Yong ;
Tuereci, Oezlem ;
Tompkins, Kristin R. ;
Lyke, Kirsten E. ;
Raabe, Vanessa ;
Dormitzer, Philip R. ;
Jansen, Kathrin U. ;
Sahin, Ugur ;
Gruber, William C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2439-2450